Enanta Pharmaceuticals Inc (NASDAQ:ENTA)
| Market Cap | $222.19M-44.2% |
| Revenue (ttm) | $63.00M-3.6% |
| Net Income | -$68.25M+16.7% |
| EPS | -$2.35+38.8% |
| Shares Out | 29.16M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 457,635 |
| Open | $7.82 |
| Previous Close | $7.98 |
| Day's Range | $7.56 - $7.99 |
| 52-Week Range | $7.56 - $17.15 |
| Beta | 0.96 |
| Analysts | Buy |
| Price Target | $20.00(+162.47%) |
| Earnings Date | Feb 8, 2027 |
About ENTA
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating ENTA in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 8, 2027Earnings report
$ENTA stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ENTA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ENTA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ENTA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ENTA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ENTA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ENTA
| VTIVanguard Morningstar Total Stock Market ETF | $7.40M |
| IWMiShares Russell 2000 ETF | $5.77M |
| VXFVanguard Extended Market ETF | $3.14M |
| VTWOVanguard Russell 2000 ETF | $1.78M |
| SLYSPDR S&P 600 Small Cap ETF | $1.77M |
| IBBiShares Biotechnology ETF | $1.63M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ENTA’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q4 earnings miss on revenue with net loss, though loss narrowed; mixed underlying fundamentals weigh on sentiment.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| GERM | ETFMG Treatments, Testing and Advancements ETF | 0.62% |
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.49% |
| SBIO | ALPS Medical Breakthroughs ETF | 0.21% |
| SLY | SPDR S&P 600 Small Cap ETF | 0.10% |
| DMRS | DeltaShares S&P 600 Managed Risk ETF | 0.09% |
| IWC | iShares Micro-Cap ETF | 0.08% |
| FSEV | Fidelity Enhanced Small Cap Value ETF | 0.06% |
| STSB | iShares Factors US Small Blend Style ETF | 0.05% |
| FEAC | Fidelity Covington Trust - Fidelity Enhanced U.S. All-Cap Equity ETF | 0.05% |
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 0.05% |
| IBB | iShares Biotechnology ETF | 0.02% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.02% |
Weight is the stock’s share of each fund’s holdings.
